Bayer adds $1.37 billion to Roundup litigation reserves to address ongoing U.S. lawsuits claiming this weed killer causes cancer

Bayer has added €1.2 billion ($1.37 billion) to its litigation reserves in response to ongoing legal challenges in the United States related to its Roundup weed killer, the company said Thursday, according to the Reuters report.

The German pharmaceutical and biotechnology group has now spent approximately $10 billion in settlements related to allegations that the glyphosate-based herbicide causes cancer. Plaintiffs have claimed that exposure to Roundup led to cases of non-Hodgkin’s lymphoma and other cancers. Bayer has since replaced glyphosate in its U.S. consumer product lines.

In a statement, Bayer said it had reached a major settlement agreement with a plaintiffs’ law firm, bringing the number of unresolved U.S. glyphosate cases down to 61,000. Of the 192,000 total claims filed, 131,000 have either been settled or dismissed as ineligible.

Alongside the litigation update, Bayer raised its full-year 2025 sales forecast to a range of €46 billion to €48 billion, up from a previous estimate of €45 billion to €47 billion. The company also expects 2025 adjusted EBITDA to fall between €9.7 billion and €10.2 billion.

Bayer reported preliminary second-quarter revenue of €10.7 billion, with adjusted EBITDA before special items at approximately €2.1 billion. The company is scheduled to release its full second-quarter results on August 6.